Pfizer India, will become the first Indian pharmaceutical company to seek emergency use approval from Drugs Controller General of India’s (DGCI) authorization for its Covid-19 vaccine candidate.
Meanwhile, Pfizer’s parent company, has already received an approval for emergency usage in the United Kingdom and Bahrain. As per an official source, “Pfizer India has sought permission for emergency usage authorization of its Covid-19 from DGCI to import and market.”
Earlier, on December 4, Pfizer India passed it’s application to DGCI seeking emergency usage authorization of its Covid-19 vaccine candidate. The application was submitted via form CT-18 for permission with respect to importing and marketing Pfizer BioNTech’s Covid-19 vaccine in India. Though, India has a very tough challenge to maintain low temperature of minus 70 degree Celsius for vaccine storage.
After the UK Regulator Medicines and Healthcare products Regulatory Agency (MHRA) granted emergency usage authorization approval on December 2 for the Covid-19 vaccine candidate in the UK. Alongside, on Friday, Bahrain also granted permission for the two dose vaccine developed by Pfizer and its German collaborator BioNTech.
- Ravichandran Ashwin Announces Sudden Retirement from International Cricket
- Free Cancer Vaccine Distribution in Russia from 2025: A Remarkable Medical Breakthrough
- Train Services Delayed Between Bengaluru-Mysuru: Introduction of New Train Numbers
- One Nation, One Election Bill Presented in Lok Sabha: Strong Opposition from Parties
- Tragic Accident in Raichur: Overturned Lorry Kills Three PWD Officials
